NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free OGEN Stock Alerts $1.57 -0.05 (-3.09%) (As of 03:39 PM ET) Add Compare Share Share Today's Range$1.57▼$1.6750-Day Range$1.01▼$3.0952-Week Range$1.00▼$7.74Volume12,145 shsAverage Volume100,835 shsMarket Capitalization$7.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Oragenics alerts: Email Address Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About Oragenics Stock (NYSE:OGEN)Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesJune 12, 2024 | americanbankingnews.comOragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.comMay 22, 2024 | globenewswire.comOragenics Appoints William “Frank” Peacock MD as Chief Clinical OfficerJune 18, 2024 | DTI (Ad)The best trading strategy for markets right nowAre we in a bull market or about to head into a recession? Will there be war or will there be peace? Will interest rates rise or go lower? Who knows! And I don’t really care. Because I’ve discovered a trading strategy that doesn’t depend on what the rest of the world is doing. But with just one trade, I can target up to $2k or more in trade income every single week, starting with as little as $500. May 17, 2024 | globenewswire.comOragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineMay 16, 2024 | msn.comOragenics climbs 9% amid Phase 2 study, business updatesMay 16, 2024 | finance.yahoo.comOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialMay 16, 2024 | investorplace.comOGEN Stock Earnings: Oragenics Reported Results for Q1 2024May 11, 2024 | finance.yahoo.comOragenics, Inc. (OGEN)June 18, 2024 | DTI (Ad)The best trading strategy for markets right nowAre we in a bull market or about to head into a recession? Will there be war or will there be peace? Will interest rates rise or go lower? Who knows! And I don’t really care. Because I’ve discovered a trading strategy that doesn’t depend on what the rest of the world is doing. But with just one trade, I can target up to $2k or more in trade income every single week, starting with as little as $500. May 7, 2024 | msn.comOragenics partners with Avance Clinical for Phase 2 concussion studyMay 7, 2024 | finance.yahoo.comOragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaApril 27, 2024 | finance.yahoo.comOragenics, Inc. (OGEN) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | finance.yahoo.comOdyssey Health, Inc. (ODYY)April 19, 2024 | businesswire.comOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsApril 17, 2024 | money.usnews.comOragenics IncApril 16, 2024 | ca.finance.yahoo.comOragenics, Inc. (OGEN) Latest Stock News & Headlines - Yahoo FinanceApril 1, 2024 | finance.yahoo.comOragenics, Inc. Files 10K and Provides Company UpdateMarch 18, 2024 | markets.businessinsider.comOragenics Appoints Kelly As Chief Medical OfficerMarch 17, 2024 | finance.yahoo.com15 Highest Quality Probiotics For Gut HealthMarch 5, 2024 | businesswire.comOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionMarch 1, 2024 | businesswire.comOragenics Announces Closing of Public OfferingMarch 1, 2024 | uk.investing.comOragenics announces public stock offeringFebruary 28, 2024 | investorplace.comWhy Is Oragenics (OGEN) Stock Down 45% Today?February 27, 2024 | markets.businessinsider.comOragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock PlungesFebruary 27, 2024 | businesswire.comOragenics Announces Pricing of Public OfferingFebruary 27, 2024 | marketwatch.comOragenics Shares Fall After Proposed Public OfferingFebruary 27, 2024 | businesswire.comOragenics Announces Proposed Public OfferingSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:OGEN Previous SymbolNYSE:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,660,000.00 Net MarginsN/A Pretax Margin-96,485.71% Return on Equity-615.16% Return on Assets-325.98% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.69 Sales & Book Value Annual Sales$40,000.00 Price / Sales175.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book2.57Miscellaneous Outstanding Shares4,480,000Free Float3,379,000Market Cap$7.03 million OptionableN/A Beta0.57 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Charles L. Pope CPA (Age 72)Executive Chairman Comp: $112.5kMr. Joseph Michael Redmond (Age 63)President & Interim Principal Executive Officer Ms. Janet Huffman (Age 52)CFO, Secretary & Treasurer Comp: $314.9kDr. James P. Kelly M.A.M.D., Chief Medical Officer & Member of Scientific AdvisorKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTBioVieNASDAQ:BIVIImmunoPrecise AntibodiesNASDAQ:IPABiora TherapeuticsNASDAQ:BIORSpruce BiosciencesNASDAQ:SPRBView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 22,675 shares on 5/20/2024Ownership: 0.506%Fred TellingSold 3,500 sharesTotal: $12,495.00 ($3.57/share)View All Insider TransactionsView All Institutional Transactions OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed in 2024? Oragenics' stock was trading at $6.1382 on January 1st, 2024. Since then, OGEN shares have decreased by 72.8% and is now trading at $1.67. View the best growth stocks for 2024 here. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) released its earnings results on Wednesday, May, 15th. The company reported ($0.70) earnings per share for the quarter. When did Oragenics' stock split? Oragenics shares reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and Who are Oragenics' major shareholders? Oragenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.51%). Insiders that own company stock include Fred Telling, Michael O'keefe Sullivan and Robert C Koski. View institutional ownership trends. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:OGEN) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
